Additionally, by subclassifying BCAS1+ oligodendrocytes into early- and late-stage cells, we explored whether specific BCAS1+ cell maturation stages in the remyelination process differentiate efficiently from poorly remyelinating MS donors and lesions. This evidence concerns the gene BCAS1 and myeloid sarcoma.